Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont's Cardiolite

This article was originally published in The Gray Sheet

Executive Summary

Investigators in the 2,456-patient Emergency Room Assessment of Sestamibi for Evaluation of chest pain (ERASE Chest Pain) study report that the Cardiolite test, as part of a chest pain evaluation protocol in the emergency room, can effectively differentiate patients suffering heart attack and in need of intensive cardiac care from those who are not. The data were presented Nov. 9 at the American Heart Association's scientific sessions in Atlanta. Funded by the Agency for Health Care Policy and Research, the study shows that such screening could lead to as much as a 20% reduction in the unnecessary admission rate of patients not in need of cardiac care
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel